Oxbryta Patent Expiration

OXBRYTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10034879 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(8 years from now)

US10806733 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(8 years from now)

US9018210 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Nov, 2033

(9 years from now)

US9447071 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491 GLOBAL BLOOD THERAPS Compounds and uses thereof for the modulation of hemoglobin
Dec, 2032

(8 years from now)

US9248199 GLOBAL BLOOD THERAPS 1:1 adducts of sickle hemoglobin
Jan, 2034

(9 years from now)

US11452720 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(10 years from now)

US10722502 GLOBAL BLOOD THERAPS Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Feb, 2035

(10 years from now)

US11020382 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Dec, 2036

(12 years from now)

US11944612 GLOBAL BLOOD THERAPS Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Dec, 2036

(12 years from now)

US10493035 GLOBAL BLOOD THERAPS Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
Oct, 2037

(13 years from now)



Oxbryta is a drug owned by Global Blood Therapeutics Inc. It is used for increasing hemoglobin levels and treating sickle cell disease by administering Voxelotor orally to patients. Oxbryta uses Voxelotor as an active ingredient. Oxbryta was launched by Global Blood Theraps in 2021. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 12, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 25, 2024
Orphan Drug Exclusivity(ODE-394) Dec 17, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: 26 November, 2023

Market Authorisation Date: 17 December, 2021

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by administering voxelotor and another active agent; Increasing hemoglobin to treat sic...

Dosage: TABLET

More Information on Dosage

OXBRYTA family patents

Family Patents